For anyone in Arbat trying to locate CJC-1295, the first thing to know is that this compound moves through online research channels. This matters because CJC-1295 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor determines everything about the product. What reliably differentiates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. The sections below cover what Arbat researchers need to know about sourcing, verifying, and handling CJC-1295 for scientific research use.
CJC-1295 Mechanisms Explained
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Arbat studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
Before looking at individual vendors, establish a quality benchmark — so you can recognise whether a vendor meets it. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. Bacteriostatic water is the correct reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 30 days refrigerated.
Order CJC-1295 — ships to Arbat
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Protocol documentation — keeping clear records of compound, timing, and method — is a fundamental research principle that ensures unusual findings can be explained.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
